Fei Ma1, Qing Li2, Xuan Zhou2, Jiangang Zhao3, Aili Song3, Wen Li2, Huan Liu2, Weili Xu1,4, Guowei Huang5. 1. Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin, 300070, China. 2. Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin, 300070, China. 3. Community Health Service Center, Sanhuailu Street, Binhai New District, Tianjin, 300456, China. 4. Aging Research Center, Department Neurobiology, Care Sciences and Society, Karolinska Institutet, 113 30, Stockholm, Sweden. 5. Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin, 300070, China. tjgwhuang@126.com.
Abstract
PURPOSE: Observational studies have frequently reported that low blood folate concentrations are associated with poor cognitive performance. Our previous studies have shown the potential beneficial effect on the metabolite levels of methionine cycle and peripheral blood inflammatory cytokines from 6- and 12-month folic acid supplementation on cognitive function in mild cognitive impairment (MCI). This study aims to continue exploring the effect of 24-month folic acid supplementation on cognitive function and pathological mechanism in MCI. METHODS:180 individuals with MCI were identified and randomly divided into intervention (folic acid 400 µg/day, n = 90) and convention (n = 90) groups. Cognitive function (WAIS-RC) and blood Aβ-related biomarkers were measured at baseline and at 6, 12, 18, and 24 months. Data were analyzed using generalized estimating equation. This trial has been registered with Trial Number: ChiCTR-TRC-13003227. RESULTS: During the follow-up, scores of full scale IQ, verbal IQ, and subdomains of Information and Digit Span were significantly higher in the intervention group than those in the convention group (P < 0.05). In the intervention group, blood homocysteine, S-adenosylhomocysteine (SAH), Aβ-42, and the expression of APP-mRNA were decreased (P < 0.05), while S-adenosylmethionine (SAM), SAM/SAH ratio, and the expression of DNA methyltransferase mRNA were increased (P < 0.05). CONCLUSION:Folic acid supplementation appears to improve cognitive function and reduce blood levels of Aβ-related biomarkers in MCI. Larger-scale double-blind placebo-controlled randomized trials of longer duration are needed.
RCT Entities:
PURPOSE: Observational studies have frequently reported that low blood folate concentrations are associated with poor cognitive performance. Our previous studies have shown the potential beneficial effect on the metabolite levels of methionine cycle and peripheral blood inflammatory cytokines from 6- and 12-month folic acid supplementation on cognitive function in mild cognitive impairment (MCI). This study aims to continue exploring the effect of 24-month folic acid supplementation on cognitive function and pathological mechanism in MCI. METHODS: 180 individuals with MCI were identified and randomly divided into intervention (folic acid 400 µg/day, n = 90) and convention (n = 90) groups. Cognitive function (WAIS-RC) and blood Aβ-related biomarkers were measured at baseline and at 6, 12, 18, and 24 months. Data were analyzed using generalized estimating equation. This trial has been registered with Trial Number: ChiCTR-TRC-13003227. RESULTS: During the follow-up, scores of full scale IQ, verbal IQ, and subdomains of Information and Digit Span were significantly higher in the intervention group than those in the convention group (P < 0.05). In the intervention group, blood homocysteine, S-adenosylhomocysteine (SAH), Aβ-42, and the expression of APP-mRNA were decreased (P < 0.05), while S-adenosylmethionine (SAM), SAM/SAH ratio, and the expression of DNA methyltransferase mRNA were increased (P < 0.05). CONCLUSION:Folic acid supplementation appears to improve cognitive function and reduce blood levels of Aβ-related biomarkers in MCI. Larger-scale double-blind placebo-controlled randomized trials of longer duration are needed.
Authors: Ai Koyanagi; Nicola Veronese; Brendon Stubbs; Davy Vancampfort; Andrew Stickley; Hans Oh; Jae Il Shin; Sarah Jackson; Lee Smith; Elvira Lara Journal: Nutrients Date: 2019-03-30 Impact factor: 5.717
Authors: Jenny McCleery; Rajesh P Abraham; David A Denton; Anne Ws Rutjes; Lee-Yee Chong; Aalya S Al-Assaf; Daniel J Griffith; Shireen Rafeeq; Hakan Yaman; Muzaffar A Malik; Marcello Di Nisio; Gabriel Martínez; Robin Wm Vernooij; Naji Tabet Journal: Cochrane Database Syst Rev Date: 2018-11-01
Authors: Florencia Andrea Ceppa; Luca Izzo; Lorenzo Sardelli; Ilaria Raimondi; Marta Tunesi; Diego Albani; Carmen Giordano Journal: Front Cell Infect Microbiol Date: 2020-07-07 Impact factor: 5.293
Authors: Hieronim Jakubowski; Anetta Zioła-Frankowska; Marcin Frankowski; Joanna Perła-Kaján; Helga Refsum; Celeste A de Jager; A David Smith Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472